CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer

BACKGROUND: Neoadjuvant therapy (NAT) is increasingly utilized for pancreatic cancer, however the added benefit of adjuvant therapy (AT) in this setting is unknown. We hypothesized that the magnitude of CA19-9 response to NAT can guide the need for further AT in resected pancreatic cancer. METHODS:...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Surg Oncol
Hlavní autoři: Liu, Hao, Zenati, Mazen S., Rieser, Caroline J., Al-Abbas, Amr, Lee, Kenneth K., Singhi, Aatur D., Bahary, Nathan, Hogg, Melissa E., Zeh, Herbert J., Zureikat, Amer H.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7931260/
https://ncbi.nlm.nih.gov/pubmed/32318949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-020-08468-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky